Everolimus, a mTOR inhibitor, is the active component of the 0.5 mg Everolimus Tablet, a prescription drug. It is used to treat a variety of cancers, including pancreatic neuroendocrine tumours and advanced renal cell carcinoma. Everolimus functions by preventing cell division and growth. The pills are swallowed, typically once daily. Fatigue, mouth sores, diarrhoea, and lowered blood cell counts are typical adverse reactions. For patients with specific malignancies, everolimus 0.5 mg offers a beneficial therapy choice that offers disease management and enhanced quality of life. To manage potential adverse effects and guarantee treatment effectiveness, regular medical monitoring is crucial during treatment.